Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Sarcoma Diagnosis and Treatment, Lung Cancer Research Studies, Lung Cancer Treatments and Mutations, and Cancer Treatment and Pharmacology.
Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma
Survival and prognostic factors of patients with esophageal fistula in advanced esophageal squamous cell carcinoma
Clinical factors affecting prognosis of limb osteosarcoma in China: a multicenter retrospective analysis
Evaluation of thyroid-stimulating hormone-increased, hypertriglyceridemia and proteinuria as markers of anlotinib efficacy in advanced soft tissue sarcoma.
Efficacy of anlotinib in advanced soft tissue sarcoma by age, gender, and ECOG performance status.
Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)
The effect of treatment line on the efficacy of anlotinib hydrochloride in advanced alveolar soft part sarcoma patients
Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial.
Macrophage-derived CCL18 promotes osteosarcoma proliferation and migration by upregulating the expression of UCA1
Review and analysis of the treatment of polycentric osteosarcoma in China
Efficacy and safety of apatinib in advanced soft tissue sarcoma: A multi-center, open-label phase II clinical trial.
Efficacy of anlotinib in advanced soft tissue sarcoma by prior lines of therapy, age and dose modification
Evaluation of hypertension and hand-foot syndrome as markers of anlotinib efficacy in advanced soft tissue sarcoma
Phase II study of anlotinib for treatment of advanced soft tissues sarcomas.
Efficacy and safety of denosumab from a phase III, randomized, active-controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors.
Berberine induces apoptosis in human multiple myeloma cell line U266 through hypomethylation of p53 promoter
A multicentre randomised trial comparing weekly paclitaxel+S-1 with weekly paclitaxel+5-fluorouracil for patients with advanced gastric cancer